- HLS Therapeutics ( OTCPK:HLTRF ) signed an agreement with Ontario, for listing and public reimbursement of heart drug Vascepa on the province's Public Prescription Drug Insurance Plan.
- Under the Product Listing Agreement (PLA), which was effective July 21, Vascepa will be reimbursed for the secondary prevention of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with established cardiovascular disease and elevated triglycerides.
- The company said reimbursement for Vascepa in Canada is now at more than 65% for publicly covered lives and private coverage is in excess of 95% for those who are in-label.
- In June, the company signed PLAs for the drug with New Brunswick, Northwest Territories and the Non-Insured Health Benefits (NIHB) for First Nations and Inuit peoples.
- HLS has licensed exclusive rights to Vascepa for the Canadian market from Amarin ( NASDAQ: AMRN ).
For further details see:
HLS Therapeutics gets reimbursement for Vascepa in Ontario